Eli Lilly’s Potential One-Two Punch for Zyprexa Users
Talk about ironies.
Eli Lilly announced yesterday that it has acquired the exclusive worldwide rights to develop and commercialize Transition Therapeutics’ gastrin-based diabetes therapies, which reportedly improve glycemic control in studies. One of these therapies is in early Phase II testing.
The acquisition should be good news for patients who take Eli Lilly’s Zyprexa drug, whose potential side effects apparently include obesity and diabetes. The drugmaker is currently being sued by about 10 states for not properly informing patients of these risks.
That said, Lilly getting the rights to the diabetes treatment seems akin to Philip Morris acquiring the worldwide rights to the cure for lung cancer. You know what they say about covering your bases…
Speaking of Zyprexa lawsuits, if you are interested in some impressive and insightful commentary on one of Lilly’s most recent PR gaffes — issuing one of the more dubious news releases I’ve ever seen — I highly recommend you check out this website.